4DMedical receives FDA clearance for CTVQ
Filed with ASX · · 4 pages · English
Summary by 6ix AI
4DMedical Ltd. has received FDA clearance for its CT:VQ™ product, marking a significant advancement in respiratory diagnostics. This technology is the first non-contrast imaging modality capable of providing quantitative ventilation and perfusion analysis from standard chest CT scans. The company anticipates capturing a substantial share of the market for ventilation-perfusion scans, which is currently dominated by nuclear imaging techniques.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- FY2025 Full year results
- Appendix 4E - Preliminary Final Report
- 4DMedical secures $10mstrategic invest' from Pro Medicus
- 4DMedical renews 3 year contract with University of Michigan
- Lung Scan Technology Reveals Hidden Secrets of Airway Disease
Later from 4DMedical
- 4DMedical receives $6.0m R&D Tax Incentive
- 4DMedical gains U.S. CMS reimbursement for CTVQ
- 4DMedical's CT: VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology
- S&P DJI Announces September 2025 Quarterly Rebalance
- 4DX signs agreements with national lung screening sites
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical